Ofloxacin treatment of nongonococcal urethritis. A multi-center study in Asia.
Ofloxacin, a new quinolone antibacterial agent, is active in vitro against gonococcal and nongonococcal urogenital pathogens. Chlamydia trachomatis infection is the most common cause of nongonococcal urethritis. In a multicenter study in seven Asian countries, 105 mal patients with chlamydial urethritis and 46 male patients with nongonococcal and nonchlamydial urethritis were treated with oral ofloxacin at a dosage of 200 mg twice daily for 5 to 10 days. The evaluation performed at day 5 and/or day 10 after treatment revealed good results in 58.2% and 96.8% of the chlamydial urethritis group, and 73.1% and 79.4% of the nongonococcal, nonchlamydial urethritis group, respectively. No severe side effects were observed. Ten-day treatment with ofloxacin showed good clinical efficacy on nongonococcal urethritis.
Kawada
Y
Y
Department of Urology, Gifu University School of Medicine, Japan.
Lee
J M
JM
Saito
I
I
Lai
C
C
Chang
L S
LS
Limson
B M
BM
Polnikorn
N
N
Daili
S F
SF
D001208:Asia; D002690:Chlamydia Infections / Q000188:drug therapy* / Q000382:microbiology; D002692:Chlamydia trachomatis / Q000302:isolation & purification; D006801:Humans; D008297:Male; D015337:Multicenter Studies as Topic; D015242:Ofloxacin / Q000009:adverse effects / Q000627:therapeutic use*; D014526:Urethritis / Q000188:drug therapy* / Q000382:microbiology
D015242:Ofloxacin